Indaptus Therapeutics (INDP) director David Natan reports zero holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Indaptus Therapeutics, Inc. director David Natan filed an initial ownership report stating that he currently holds no shares of the company. The filing shows that he has no beneficial ownership of non-derivative or derivative securities of Indaptus as of the event date, and his position is reported as a director filing on his own behalf.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
NATAN DAVID
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | No securities are beneficially owned. | -- | -- | -- |
Holdings After Transaction:
No securities are beneficially owned. — 0 shares (Direct)
Footnotes (1)
FAQ
What does the latest Form 3 for INDP show about David Natan?
The Form 3 shows that director David Natan reports no securities beneficially owned in Indaptus Therapeutics, Inc.
What is David Natan’s relationship to Indaptus Therapeutics (INDP)?
David Natan is reported as a director of Indaptus Therapeutics, Inc. and is not listed as an officer or 10% owner in this Form 3.
What transaction information is included in this INDP Form 3 filing?
The Form 3 is an initial ownership report and indicates a holding position with 0.0000 shares beneficially owned following the reported date.
Are there any derivative securities reported for the INDP director?
No. The section for Derivative Securities Beneficially Owned contains no entries, indicating no reportable derivative positions.